Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Production and Processing Studies to Reduce the Incidence of Salmonellae on Commercial Broilers <sup>1,</sup> <sup>2</sup>.

Journal of food protection·2019
Same author

Comparison of the DNA Probe to Culture Methods for the Detection of Salmonella on Poultry Carcasses and Processing Waters <sup>1</sup>.

Journal of food protection·2019
Same author

Histamine drives severity of innate inflammation via histamine 4 receptor in murine experimental colitis.

Mucosal immunology·2018
Same author

ESSENTIAL TRACE METALS IN MAN: MOLYBDENUM.

Journal of chronic diseases·2015
Same author

Dysregulation of the Wnt pathway in adult eosinophilic esophagitis.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2014
Same author

Pathogenesis of hypertension.

The Washington University medical alumni quarterly·2014
Same journal

Retraction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.

The Journal of experimental medicine·2026
Same journal

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.

The Journal of experimental medicine·2026
Same journal

Flawed translation triggers oncogenic B-T cell communication.

The Journal of experimental medicine·2026
Same journal

Correction: LCK'ed in: Inborn errors of immunity in LCK reveal how TCR signaling is calibrated.

The Journal of experimental medicine·2026
Same journal

Mechanobiology of inflammation: Pulling the strings of innate immunity.

The Journal of experimental medicine·2026
Same journal

Bile acid retention in efferocytic macrophages shapes their inflammatory status during cholangitis.

The Journal of experimental medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

THE EFFECT OF TYROSINASE ON EXPERIMENTAL HYPERTENSION.

H A Schroeder1, M H Adams

  • 1Hospital of The Rockefeller Institute for Medical Research.

The Journal of Experimental Medicine
|October 30, 2009
PubMed
Summary
This summary is machine-generated.

Mushroom tyrosinase effectively lowers blood pressure in hypertensive rats and dogs. This enzyme inactivates key blood pressure-raising substances, offering a potential treatment for experimental hypertension without harming kidney function.

Related Experiment Videos

Last Updated: Jun 19, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Area of Science:

  • Biochemistry
  • Pharmacology
  • Physiology

Background:

  • Arterial hypertension is a significant health concern with complex underlying mechanisms.
  • Existing treatments for hypertension can have limitations and side effects.
  • The role of enzymes like tyrosinase in blood pressure regulation is an area of ongoing research.

Purpose of the Study:

  • To investigate the effects of tyrosinase on experimental arterial hypertension in animal models.
  • To determine if tyrosinase can lower blood pressure in hypertensive subjects.
  • To explore the potential of tyrosinase as a therapeutic agent for hypertension.

Main Methods:

  • Intravenous and intramuscular administration of tyrosinase to hypertensive rats and dogs.
  • In vitro inactivation assays of tyrosinase against pressor substances like renin and angiotonin.
  • Assessment of renal function in hypertensive dogs treated with tyrosinase.

Main Results:

  • Tyrosinase consistently lowered blood pressure in rats and dogs with experimentally induced hypertension.
  • Normal animals showed minimal blood pressure changes after tyrosinase injection.
  • Tyrosinase demonstrated in vitro inactivation of renin, angiotonin, and other pressor agents.
  • Renal function remained unaffected in hypertensive dogs following blood pressure reduction by tyrosinase.

Conclusions:

  • Tyrosinase effectively reduces blood pressure in experimental models of arterial hypertension.
  • The blood pressure-lowering effect is likely due to the inactivation of pressor substances.
  • Tyrosinase presents a promising therapeutic candidate for managing hypertension, with no observed adverse effects on renal function.